Jo Shorthouse
Interim Editor of In Vivo
Jo Shorthouse is the Interim Editor of In Vivo. She has contributed to various Pharma Intelligence publications, starting with Scrip in 2008. She has previously edited Scrip Good Clinical Practice, Scrip Clinical Research and the Scrip 100, been a managing editor on Pharma Intelligence’s Commercial team, and most recently turned her hand to freelance health care journalism and editorial consultancy. Jo has a wide-ranging knowledge of many aspects of the pharmaceutical industry which allows her to bring insights to the Pharma Intelligence and In Vivo teams.
Latest From Jo Shorthouse
Citeline And Norstella Merge To Provide End-To-End Solutions For Pharma
Publisher’s Spotlight: Citeline, the publisher of In Vivo, is to merge with fellow pharmaceutical solutions provider Norstella.
Funding The Future: Accelerating The Long Walk To Innovation
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.
Partnerships Picks For GeNeuro’s MS Antibody
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
Muvon Therapeutics: The Road To Expansion
Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.
Turning The Dial Up On Digital
The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.
A New Generation Invents Pharma’s Mirrored Future
Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.